IMUX
Companies
NASDAQ
Immunic Inc.
Health Care
$0.75
-$0.27 (-26.99%)
Price Chart
Overview
About IMUX
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Market Cap
$110.8M
Volume
581.4K
Avg. Volume
514.8K
P/E Ratio
-1.5040625
Dividend Yield
0.00%
Employees
67.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.19
Moderate Correlation
Volatility
High (0.71)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IMUX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$110.8M
Volume581.4K
P/E Ratio-1.50
Dividend Yield0.00%
Important Dates
Next Dividend
April 15, 2019Next Earnings
November 7, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025